Unverified data about events after vaccinations is not evidence that the vaccine caused the event, as suggested in social ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

How durable are the mRNA Covid vaccines? Does the protection last as long as other vaccines? Experts the vaccines are ...

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

The no-cost clinic will offer flu vaccines and Pfizer COVID-19 shots on a first-come ... protect themselves from the virus ...

Pfizer's earnings were better than investors and management ... Its antiviral pill for treating COVID-19, Paxlovid, and its COVID vaccine, Comirnaty, are also performing a bit more strongly than it ...

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...